The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

Roy W Jones; Miia Kivipelto; Howard Feldman; Larry Sparks; Rachelle Doody; David D Waters; Judith Hey-Hadavi; Andrei Breazna; Rachel J Schindler; Harry Ramos; LEADe Investigators; Peter Passmore

doi:10.1016/j.jalz.2008.02.001

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

Roy W Jones, Miia Kivipelto, Howard Feldman, Larry Sparks, Rachelle Doody, David D Waters, Judith Hey-Hadavi, Andrei Breazna, Rachel J Schindler, Harry Ramos, LEADe Investigators, Peter Passmore

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Abstract

Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

Original language	English
Pages (from-to)	145-53
Number of pages	9
Journal	Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.jalz.2008.02.001
Publication status	Published - Mar 2008

ASJC Scopus subject areas

Epidemiology
Geriatrics and Gerontology
Health Policy
Clinical Neurology
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Developmental Neuroscience

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jalz.2008.02.001

Cite this

Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., Hey-Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., LEADe Investigators, & Passmore, P. (2008). The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 4(2), 145-53. https://doi.org/10.1016/j.jalz.2008.02.001

@article{13e78021f724442bbf40a54555f76141,

title = "The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics",

abstract = "Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).",

author = "Jones, \{Roy W\} and Miia Kivipelto and Howard Feldman and Larry Sparks and Rachelle Doody and Waters, \{David D\} and Judith Hey-Hadavi and Andrei Breazna and Schindler, \{Rachel J\} and Harry Ramos and \{LEADe Investigators\} and Peter Passmore",

year = "2008",

month = mar,

doi = "10.1016/j.jalz.2008.02.001",

language = "English",

volume = "4",

pages = "145--53",

journal = "Alzheimer's \& Dementia: The Journal of the Alzheimer's Association",

publisher = "John Wiley \& Sons Inc.",

number = "2",

}

Jones, RW, Kivipelto, M, Feldman, H, Sparks, L, Doody, R, Waters, DD, Hey-Hadavi, J, Breazna, A, Schindler, RJ, Ramos, H, LEADe Investigators & Passmore, P 2008, 'The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics', Alzheimer's & Dementia: The Journal of the Alzheimer's Association, vol. 4, no. 2, pp. 145-53. https://doi.org/10.1016/j.jalz.2008.02.001

TY - JOUR

T1 - The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe)

T2 - design and baseline characteristics

AU - Jones, Roy W

AU - Kivipelto, Miia

AU - Feldman, Howard

AU - Sparks, Larry

AU - Doody, Rachelle

AU - Waters, David D

AU - Hey-Hadavi, Judith

AU - Breazna, Andrei

AU - Schindler, Rachel J

AU - Ramos, Harry

AU - LEADe Investigators

AU - Passmore, Peter

PY - 2008/3

Y1 - 2008/3

N2 - Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

AB - Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

U2 - 10.1016/j.jalz.2008.02.001

DO - 10.1016/j.jalz.2008.02.001

M3 - Article

C2 - 18631958

VL - 4

SP - 145

EP - 153

JO - Alzheimer's & Dementia: The Journal of the Alzheimer's Association

JF - Alzheimer's & Dementia: The Journal of the Alzheimer's Association

IS - 2

ER -

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this